Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study

Background The phase 3 randomized PERSIST study demonstrated the efficacy and tolerability of galcanezumab, a humanized anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for prevention of episodic migraines. We present findings from the open-label extension (OLE) of PERSIST, which eval...

Full description

Bibliographic Details

Published in:	The Journal of Headache and Pain
Main Authors:	Jiying Zhou, Lianmei Zhong, Debashish Chowdhury, Kirill Skorobogatykh, Guogang Luo, Xiaosu Yang, Mingjie Zhang, Lingli Sun, Hui Liu, Chenxi Qian, Shengyuan Yu
Format:	Article
Language:	English
Published:	BMC 2023-08-01
Subjects:	Calcitonin gene-related peptide Galcanezumab Humanized monoclonal antibody Episodic migraine”
Online Access:	https://doi.org/10.1186/s10194-023-01613-1